Elephas Biosciences, University of Louisville Form Research Partnership to Study Immunotherapy Response in GI Cancers

Elephas Biosciences Corporation, a privately held Madison, Wisconsin-based company focused on live tissue immunotherapy response prediction, has entered into a research partnership with the University of Louisville to evaluate combination therapy involving surgical intervention and immunotherapy across three gastrointestinal cancer types. The collaboration will deploy the Elephas Live platform in conjunction with three investigator-initiated trials targeting advanced-stage colorectal, pancreatic, and liver cancer.

Financial terms of the partnership were not disclosed. Elephas is a private company with no publicly traded equity, and the University of Louisville is a public research institution. The arrangement is structured as an academic research collaboration rather than a traditional pharmaceutical licensing transaction with upfront payments, milestones, or royalties.

Elephas Biosciences Brings Ex Vivo Functional Assay to Academic Oncology

Under the terms of the partnership, the University of Louisville will integrate the Elephas Live platform into its Surgical Oncology Research Laboratory, led by Robert Martin, M.D., Ph.D., Vice Chair for the Department of Surgery and Professor/Director of Surgical Oncology Research. The laboratory will analyze live tumor specimens on the platform in conjunction with multiple investigator-initiated trials designed to assess how individual patients' tumors respond to immunotherapy in real time, particularly when combined with surgical intervention.

The Elephas Live platform is an ex vivo functional assay system that preserves the native tumor microenvironment from a standard core needle biopsy and measures immune response activation within intact, living tissue when exposed to immunotherapy agents. The company has stated that its proprietary method addresses tumor heterogeneity — the biological variability within and across tumors that limits the predictive accuracy of conventional molecular biomarkers such as PD-L1 expression, tumor mutational burden, and microsatellite instability status.

The three investigator-initiated trials will span colorectal, pancreatic, and liver cancer, though the specific immunotherapy agents to be used in these trials were not identified in the announcement. The press release referenced immunotherapy as a drug class without naming individual molecules or checkpoint targets.

Solid Tumor Immunotherapy Prediction Remains an Unmet Need

The partnership is positioned against a well-documented challenge in solid tumor immunotherapy: response rates to immune checkpoint inhibitors remain limited across most GI malignancies. Elephas cited a figure of approximately one in five cancer patients benefiting from immunotherapy, a statistic consistent with published literature on PD-1/PD-L1 blockade response rates in unselected solid tumor populations.

Existing biomarker-based patient selection tools have not resolved this problem. PD-L1 immunohistochemistry, microsatellite instability testing, and tumor mutational burden assessment each capture a subset of likely responders but fail to predict outcomes for a substantial proportion of patients. Many PD-L1-high patients do not respond to checkpoint blockade, while some PD-L1-low patients derive benefit. The field has recognized that static molecular biomarkers are insufficient proxies for the dynamic, spatially complex immune interactions occurring within the tumor microenvironment.

Functional assays that test drug response on living tissue represent one approach to closing this prediction gap. The Elephas Live platform falls into this category, aiming to provide a direct readout of immune activation rather than an indirect inference from molecular markers.

University of Louisville Cancer Research Adds Clinical Infrastructure

The University of Louisville is classified by the Carnegie Foundation as both a Research 1 and Community Engaged institution, one of 79 universities in the United States holding both designations. Martin's laboratory brings surgical oncology expertise and access to patient populations with advanced-stage GI cancers — tumor types that remain among the most difficult to treat.

Advanced-stage colorectal, pancreatic, and liver cancers carry poor prognoses and limited treatment options. Pancreatic ductal adenocarcinoma has a five-year survival rate in the single digits for metastatic disease. Hepatocellular carcinoma and metastatic colorectal cancer have seen incremental survival gains from checkpoint inhibitor combinations in recent years, but durable responses remain confined to biomarker-selected subsets.

Martin stated that the collaboration would allow his team to "move beyond population-based treatment strategies toward truly individualized therapeutic decision-making," adding that "precision tools that help tailor therapy to each patient's tumor biology are essential to improving outcomes."

Elephas Live Platform Faces a Crowded Checkpoint Inhibitor Landscape

The competitive context for the platform's utility is shaped by the proliferation of PD-1 and PD-L1 inhibitors now approved or in late-stage development for GI indications. Pembrolizumab, nivolumab, atezolizumab, durvalumab, tislelizumab, dostarlimab, and multiple China-originated agents including sintilimab, camrelizumab, and toripalimab all hold approvals or are in registrational trials across colorectal, hepatocellular, biliary, gastric, and esophageal cancers.

With more than ten approved anti-PD-1/PD-L1 agents and limited clinical differentiation between them in most settings, the competitive dynamic increasingly favors tools that can match individual patients to the therapy most likely to produce a response. This is the commercial and clinical logic underlying the Elephas platform: as checkpoint inhibitor options multiply, the value of accurate functional prediction rises.

The emergence of next-generation combination approaches adds further complexity. Agenus's botensilimab plus balstilimab combination has reported response rates in microsatellite-stable colorectal cancer, a population historically refractory to all checkpoint regimens. Bispecific antibodies targeting PD-1 alongside VEGF or CTLA-4 — including Akeso's ivonescimab and cadonilimab — are in Phase III development across GI tumors. Each new combination increases the number of therapeutic options a clinician must evaluate for a given patient, reinforcing the rationale for a platform that can test multiple agents on living tissue before committing to a treatment course.

Elephas Biosciences Expands Academic Collaboration Footprint

The University of Louisville partnership is consistent with a broader pattern of academic collaborations for Elephas. The company has referenced multi-institutional observational prospective clinical trials — designated ELEPHAS-01, ELEPHAS-02, and ELEPHAS-04 — in conference presentations, including materials submitted to the American Society of Clinical Oncology. A ClinicalTrials.gov registration (NCT06349642) has been associated with the company's clinical validation program, though detailed protocol information from that record was not available for this report.

Maneesh Arora, Elephas Founder and CEO, described the Louisville partnership as part of the company's global commercialization strategy. "Progress in oncology depends on strong collaborations that bring together clinical expertise and advanced technology," Arora stated.

The company did not disclose whether the University of Louisville will receive access to the platform at no cost, under a fee-for-service arrangement, or through another structure. The investigator-initiated trial designation indicates that the clinical studies are designed and sponsored by the academic investigators rather than by Elephas, though the company's platform provides the analytical infrastructure.

No timeline was provided for data readouts from the three trials, and no endpoints or enrollment targets were disclosed in the announcement.

---

Spot something wrong? Report an issue with this article